Clinical Trial Update: Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) [Phase 2]

View source ↗

Summary

A Phase 2 MATCH subprotocol evaluating AZD5363 (capivasertib) for cancers with AKT genetic alterations; the study is marked as active but not recruiting, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• AZD5363 (Capivasertib) (capivasertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-08-10